Study summary
Treating high-risk smoldering myeloma early with daratumumab halved progression and improved survival
63.1%progression-free at 5 years, vs 40.8% with monitoring
What was tested
Subcutaneous daratumumab, a CD38 antibody, given for up to 3 years, against active monitoring, for high-risk smoldering multiple myeloma (no symptoms or organ damage yet).
What they found
- 5-year progression-free survival was 63.1% vs 40.8% (51% lower risk).
- 5-year overall survival was 93.0% vs 86.9%.
- Only 5.7% stopped because of side effects.
What it means
The first approved treatment for smoldering myeloma, changing the long-standing "watch and wait" rule for high-risk people.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.